Neuronetics Schedules Q4 2025 Earnings Release and Conference Call
Event summary
- Neuronetics to release Q4 2025 financial and operating results on March 17, 2026.
- Conference call scheduled for 8:30 a.m. Eastern Time on the same day.
- Company operates Greenbrook treatment centers offering NeuroStar Therapy, SPRAVATO, and other mental health treatments.
- NeuroStar Therapy is FDA-cleared for treatment of MDD, OCD, and comorbid anxiety symptoms.
The big picture
Neuronetics' upcoming earnings release comes at a time when the mental health sector is experiencing increased demand for non-drug, noninvasive treatments. The company's strategic focus on expanding its treatment options and operating its own treatment centers positions it to capitalize on this trend. The market will be watching closely to see if Neuronetics can maintain its momentum in a competitive landscape.
What we're watching
- Revenue Growth
- Whether Neuronetics can sustain its growth trajectory in the neurohealth therapies market.
- Regulatory Compliance
- The pace at which regulatory approvals for NeuroStar Therapy expand into new indications.
- Operational Efficiency
- How the integration of Greenbrook treatment centers impacts operational costs and revenue.